Hinova Pharmaceuticals Valuation

Is 688302 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688302 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 688302's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 688302's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688302?

Key metric: As 688302 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 688302. This is calculated by dividing 688302's market cap by their current book value.
What is 688302's PB Ratio?
PB Ratio	2.9x
Book	CN¥1.23b
Market Cap	CN¥3.54b

688302 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	24044.3x
Enterprise Value/EBITDA	-11x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 688302's PB Ratio compare to its peers?

The above table shows the PB ratio for 688302 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	1.7x
300434 Sichuan Goldstone Asia Pharmaceutical	1.5x	n/a	CN¥3.6b
300016 Beijing Beilu Pharmaceutical	2x	n/a	CN¥3.4b
002900 Harbin Medisan Pharmaceutical	1.6x	n/a	CN¥3.3b
300636 Jiangxi Synergy Pharmaceutical	1.5x	32.9%	CN¥3.6b
688302 Hinova Pharmaceuticals	2.9x	10.2%	CN¥3.5b

Price-To-Book vs Peers: 688302 is expensive based on its Price-To-Book Ratio (2.9x) compared to the peer average (1.7x).

Price to Book Ratio vs Industry

How does 688302's PB Ratio compare vs other companies in the CN Pharmaceuticals Industry?

1 Company	Price / Book	Estimated Growth	Market Cap
002435 Changjiang Runfa Health Industry	0.1x	n/a	US$63.75m

No more companies available in this PB range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: 688302 is expensive based on its Price-To-Book Ratio (2.9x) compared to the CN Pharmaceuticals industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is 688302's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688302 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	2.9x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 688302's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hunan Jiudian Pharmaceutical

CN¥12.2b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥24.71

-0.2%

5.1%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.87

-5.5%

11.1%